Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial

The Lancet Diabetes & Endocrinology 2026

View at publisher
Authors: Toshimasa Yamauchi, Niels‐Peter Becker, Christoffer Hagemann, Kuo-Chin Huang, Arihiro Kiyosue, Soo Lim, Yukiko Onishi, Ananda Kosuvaripalli, Tomoko Takano, Yasushi Ishigaki
DOI: 10.1016/s2213-8587(25)00402-4
Cited by: 4
References: 37

Fields of Study & Subjects

Diabetes Treatment and Management Diabetes Cardiovascular Risks and Lipoproteins Bariatric Surgery and Outcomes

Publication details

Journal / source
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Volume
14
Issue
6
Pages
450–462
Publication date
17 April 2026
Language
EN